Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders. The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation…
Author: Abhay Panchal
I’m Dr Kenny Lin. I am a family physician and associate director of the Lancaster General Hospital Family Medicine Residency, and I blog at Common Sense Family Doctor. I’m 47 years old. Two years ago, when the US Preventive Services Task Force (USPSTF) followed the American Cancer Society (ACS) and lowered the starting age for colorectal cancer (CRC) screening from 50 to 45, my family physician brought up screening options at a health maintenance visit. Although I had expressed some skepticism about this change when the ACS updated its screening guideline in 2018, I generally follow the USPSTF recommendations in…
DENVER–(BUSINESS WIRE)–Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado and a subsidiary of Gastro Care Partners (“GCP”), today announced that Dr. Mary Ann Y. Huang has been named one of “Denver’s Top Doctors 2023” by local Denver magazine 5280, and recognized by Castle Connolly as one of the nation’s “Top Asian American and Pacific Islander Doctors 2023.”
In 2022, 34% of physicians earned income from a source outside their practice, the highest percentage since statistics started being tracked in 2017, indicating a rising trend of medical professionals pursuing extracurricular moneymaking opportunities. The data, published by Medical Economics, showed that consulting was the top source of secondary income for physicians, followed by teaching.
How can we use biomarkers to treat patients with ulcerative colitis? That’s the exact question the latest guideline from the American Gastroenterological Association (AGA) sought to address. Learn about this guideline and other best practices with Dr. Peter Buch and Dr. Siddharth Singh, Assistant Professor of Medicine at the University of California-San Diego and co-author of an article published in Gastroenterology in March 2023 titled “AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.
The AGA applauded the reintroduction of the Treat and Reduce Obesity Act into the 118th Congress as this bill would expand Medicare coverage for screening and treatment of obesity by health care providers specializing in obesity care. The Treat and Reduce Obesity Act of 2023 (TROA; H.R. 4818/S. 2407), a bipartisan and bicameral bill seeks coverage under Medicare Part D for FDA-approved medications to treat obesity.
In this article, the authors review various technological and practice innovations that are emerging as important considerations for GI clinical practice, including artificial intelligence, endoscopy, obesity and metabolic disorders, the microbiome, digital health and telemedicine, and environmental sustainability. They discuss limiting factors that can inhibit progress in these areas and call on the GI community to continue to drive progress and accelerate innovation.
Here are five compensation statistics gastroenterologists should know, using data from Medscape: $451,263: The national average salary among gastroenterologists of all years of experience in any practice setting. 57 percent: The percentage of gastroenterologists earning between $436,000 and $639,000.
Researchers at Denmark-based Bactolife are designing targeted protein molecules called Binding Proteins to target toxins from harmful pathogens that have infiltrated the gastrointestinal tract while leaving the beneficial gut microbiome alone. In a bid to advance its platform, the company has just raised €30m ($33m). Bactolife raised the funds in a Series A round led by ATHOS with participation from the Bill & Melinda Gates Foundation and Novo Holdings. The company previously raised €7m in seed financing in April 2021.
Barrett’s esophagus is the premalignant condition for esophageal adenocarcinoma, characterized by transformation of the normal squamous lining of the esophagus to columnar epithelium. Risk factors for BE include older age, male sex, white race, long-standing gastroesophageal reflux disease, positive family history, and tobacco smoking. Given the risk for malignant transformation, early identification of BE-related neoplasia is essential because these lesions can harbor cancer, which may be curable if identified early. With advances in endoscopic visualization and interventions, detection and characterization of both BE and BERN have improved significantly.